fMRI-Directed rTMS Targeting V1 Alleviates Depressive Symptoms in Young Individuals with Bipolar Disorder: Results from a Double-Blind Randomized Controlled Study - Scorecard - MDSpire

fMRI-Directed rTMS Targeting V1 Alleviates Depressive Symptoms in Young Individuals with Bipolar Disorder: Results from a Double-Blind Randomized Controlled Study

  • By

  • Xudong Zhao

  • Hetong Zhou

  • Xiaomei Zhang

  • Ruoyu Tang

  • Yimei Gan

  • Tongjie Zhuang

  • Yiyi Zhu

  • Zeyu Qin

  • Yiqing Chen

  • Yaoyang Fu

  • Danhua Zhang

  • Le Xu

  • Shiliang Wang

  • Zhongxia Shen

  • Shaohua Hu

  • Minmin Wang

  • March 7, 2026

  • 0 min

Share

Clinical Scorecard: fMRI-Directed rTMS Targeting V1 Alleviates Depressive Symptoms in Young Individuals with Bipolar Disorder: Results from a Double-Blind Randomized Controlled Study

At a Glance

CategoryDetail
ConditionBipolar Disorder with Depressive Symptoms (BD-D)
Key MechanismsHigh-frequency rTMS targeting the primary visual cortex (V1) to modulate orbitofrontal cortex (OFC) circuits.
Target PopulationAdolescents and young adults with bipolar disorder and depressive symptoms.
Care SettingOutpatient clinical trial setting.

Key Highlights

  • High-frequency rTMS over V1 showed efficacy in reducing depressive symptoms.
  • Study utilized a double-blind, randomized controlled design.
  • Participants received standardized lurasidone monotherapy alongside rTMS.
  • Significant changes in MADRS scores observed at week 3 post-intervention.
  • Neuroimaging assessments indicated potential circuit-level modulation.

Guideline-Based Recommendations

Diagnosis

  • Use standardized rating scales for assessing emotional symptoms.

Management

  • Consider high-frequency rTMS targeting V1 as an adjunctive treatment for BD-D.

Monitoring & Follow-up

  • Regularly assess MADRS scores and monitor for adverse events.

Risks

  • Monitor for potential adverse effects associated with rTMS and pharmacological treatment.

Patient & Prescribing Data

Adolescents and young adults diagnosed with bipolar disorder.

Lurasidone monotherapy was maintained throughout the rTMS intervention.

Clinical Best Practices

  • Ensure blinding and randomization in clinical trials to reduce bias.
  • Utilize fMRI data to guide rTMS targeting for improved outcomes.
  • Monitor patient compliance and tolerability during treatment.

References

Original Source(s)

fMRI-Directed rTMS Targeting V1 Alleviates Depressive Symptoms in Young Individuals with Bipolar Disorder: Results from a Double-Blind Randomized Controlled Study

  • by Xudong Zhao, Hetong Zhou, Xiaomei Zhang, Ruoyu Tang, Yimei Gan, Tongjie Zhuang, Yiyi Zhu, Zeyu Qin, Yiqing Chen, Yaoyang Fu, Danhua Zhang, Le Xu, Shiliang Wang, Zhongxia Shen, Shaohua Hu, Minmin Wang

  • March 7, 2026

Related Content

Medical Oddities: Can a Home Be Preventive Care?

This week’s medical plot twists involved ants, architecture, and auditory hallucinations.

Toward Participatory Precision Health With Co-Designed Recommendations: Systematic Review of Just-in-Time Adaptive Interventions in Adolescents and Young Adults

Could Digital Twins Forecast Forensic Risk?

Researchers outline a proposed three-level framework spanning patient monitoring, ward operations, and forensic system planning.